Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
Neuroblastoma UK announces new 2021 Grant Round
We are delighted to announce the launch of our new research Grant Round for 2021.
Postponed from 2020 due to the coronavirus pandemic, our biennial grant round for 2021 will focus on applications for research that will have the greatest potential impact to improve treatment for children with neuroblastoma.
Developing personalised treatment for ALK-positive neuroblastoma
Thanks to funding from Neuroblastoma UK, post-doctoral research associate Dr Perla Pucci was recruited to join a neuroblastoma research team at the University of Cambridge.
The team, led by Dr Suzanne Turner, are looking to develop more personalised treatment for children with ALK-positive neuroblastoma. Perla tells us more about how the project has progressed.
New immunotherapy shows promise for treating neuroblastoma
A novel CAR T-cell therapy designed to target cancerous tumours has shown promising early results in treating children with neuroblastoma.
The original pre-clinical work was funded by Neuroblastoma UK to help launch the study. Dr Karin Straathof, one of the lead investigators on the study, tells us more.
Understanding potential cancer-causing proteins to improve neuroblastoma treatment
In 2019, Neuroblastoma UK provided a grant of £143,648 to Dr Andrew Stoker and his team at University College London.
The team want to investigate how a particular protein that is well known to promote tumours in several cancers including breast, lung and prostate cancer works in neuroblastoma cells.
A potential new treatment for neuroblastoma
We welcome the news that a potential new treatment for children with neuroblastoma will be advanced to clinical trial and reach more young cancer patients.
Researchers have found an indirect way to target N-Myc, a gene that occurs in aggressive forms of neuroblastoma. They found that a new drug, fadraciclib, is effective at blocking N-Myc activity by switching off the production of N-Myc and a clinical trial for children with high-risk neuroblastoma is due to open by the end of 2020.
September Research News
Read the latest neuroblastoma news from September.
New insights into neuroblastoma could help better tailor treatment for children affected by this rare and aggressive cancer.
Accelerating drug development for neuroblastoma
An international forum of leading scientists from the UK, Europe and USA, funded by national charity Neuroblastoma UK, prioritises drug development and strategies for new treatment trials for children with neuroblastoma.
In the September edition of European Journal of Cancer, Dr Lucas Moreno from Vall d’Hebron Hospital, Barcelona, and a team of international scientific and clinical experts published an agreed list of genetic targets and drugs that should be advanced for early-phase paediatric clinical trials, following the second Neuroblastoma New Drug Development Strategy (NDDS) forum.
SIOPEN High-Risk Neuroblastoma Clinical Trial 2 to open in the UK in 2021
Neuroblastoma UK with Solving Kids’ Cancer has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK. The trial is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study, enabling a series of important randomised questions to be answered within the overall framework of the trial.
Press release: Charities fund new clinical trial to help children with cancer
Neuroblastoma UK and Solving Kids Cancer have awarded a grant to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study.
Committed to our cause
The current and rapidly evolving situation with coronavirus presents significant challenges for the research community and every sector.
The coronavirus and government guidelines are already having a significant impact on neuroblastoma research, now and in the future. These changes, whilst temporary and very much supported by all of us at Neuroblastoma UK, may affect the pace and progress of vital neuroblastoma research.